Background: Enzalutamide is a potent androgen-signaling receptor inhibitor and is licensed for the treatment of metastatic castration-resistant prostate cancer. N-desmethylenzalutamide is the active metabolite of enzalutamide. A method to quantitate enzalutamide and its active metabolite was developed and validated according to the European Medicine Agency guidelines.
INTRODUCTION
Enzalutamide (Xtandi) is a potent androgen-signaling receptor inhibitor and is licensed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Enzalutamide improved progression-free survival and overall survival in phase III trials in the prechemotherapy and postchemotherapy setting. 1,2 One of the 2 major metabolites identified in human plasma is active: N-desmethylenzalutamide is equipotent in vitro and is present at similar plasma concentrations as the parent enzalutamide. 3 Enzalutamide is administered at a fixed oral dose of 160 mg once daily (OD) regardless of body surface area, age, and clinical condition. 3 Enzalutamide is highly protein bound (97%-98%) and has a mean half-life of ;5.8 days. Enzalutamide is metabolized by CYP2C8 and CYP3A4. The active metabolite, N-desmethylenzalutamide, is formed through CYP2C8 metabolism. Enzalutamide is a strong inducer of CYP3A4 and moderate inducer of CYP2C19 and CYP2C9. 3, 4 For enzalutamide, no exposure-response relationship was identified for overall survival when dosed at 160 mg, and this is expected since the interpatient variability in enzalutamide and N-desmethylenzalutamide exposure (AUC, C min , and C max ) is low (#30%). In a retrospective analysis, efficacy was similar in the 4 different exposure quartiles based on steady-state C trough . 5 This may imply that patients in the lower quartile are treated equally effectively. Therapeutic drug monitoring might therefore be useful for patients with unexpected toxicity, inefficacy, or drug interactions. The earlier described Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS) assay for the quantification of enzalutamide and its metabolites in human plasma uses liquid-liquid extraction as the sample pretreatment method. 6 In the current assay, the sample pretreatment was simplified using protein precipitation. The bioanalytical method has been developed to support clinical studies and to support patient care in the case of unexpected toxicity, inefficacy, or expected drug interactions. We describe the successfully developed and validated assay.
MATERIALS AND METHODS

Chemicals and Reagents
Enzalutamide, N-desmethylenzalutamide, and the deuterated stable isotope-labeled D 6 -enzalutamide were obtained from Alsachim (Illkirch, France); dimethyl sulfoxide (Seccosolv) and acetonitrile (ACN) (Lichrosolv) were purchased from Merck (Darmstadt, Germany). Albuman 200g/L was obtained from Sanquin (Amsterdam, the Netherlands). Formic acid was obtained from Sigma-Aldrich (Zwijndrecht, the Netherlands). High-purity Milli-Q water was produced in the laboratory using a Milli-Q Gradient water purification system (Millipore, Amsterdam, the Netherlands). Cellstar tubes (15 and 50 mL) were purchased from Greiner Bio-one (Alphen a/d Rijn, The Netherlands). Polypropylene screw vials and safe lock tubes were purchased from Agilent (Amstelveen, the Netherlands) and Eppendorf (Nijmegen, the Netherlands), respectively. Ethylenediaminetetraacetic acid plasma was prepared from ethylenediaminetetraacetic acid whole blood obtained from Sanquin (Amsterdam, the Netherlands).
Preparation of Stock Solutions, Calibration Standards, Quality Control Samples, and Internal Standard Solution
Two independent enzalutamide and N-desmethylenzalutamide stocks were used: one for the preparation of calibration standards and one for the quality control (QC) samples. Stock solutions were prepared in dimethyl sulfoxide at a nominal concentration of 1 mg/mL enzalutamide, Ndesmethylenzalutamide, and D 6 -enzalutamide (used as internal standard). For a calibration curve, the stock solutions of enzalutamide and N-desmethylenzalutamide were diluted with ACN to obtain concentration levels of 1000, 2500, 5000, 10,000, 25,000, 35,000, and 50,000 ng/mL. Before each run, the calibrators were diluted 10-fold with a 200 g/ L human albumin solution (Albuman/plasma) (90:10), to obtain a calibration curve at the following concentration levels: 100, 250, 500, 1000, 2500, and 5000 ng/mL. The QC stock solution was diluted with ACN to yield QC concentration levels of 1000, 15,000, and 40,000 ng/mL enzalutamide and N-desmethylenzalutamide, which were also subsequently diluted 10-fold with the albuman solution/plasma (90:10). The precipitation solution was prepared by adding 75-mL internal standard (IS) stock solution to 250-mL ACN.
Sample Preparation
Protein precipitation was used as sample pretreatment by adding 900 mL of precipitation solution to 100 mL of albumin solution-diluted plasma sample. The mixture was immediately vortexed for 5 minutes and centrifuged for 5 minutes at 18,620g. An aliquot of 200 mL of supernatant was transferred to a polypropylene autosampler vial.
Chromatographic Conditions
The LC-MS/MS system consisted of an Acquity HClass UPLC system, coupled to a Xevo TQ-S Micro Tandem Mass Spectrometer (Waters, Wilford, MA). Chromatographic separation was performed by injecting 2-mL supernatant onto an Acquity BEH C18 Column (2.1 · 50 mm, 1.7 mm particle size, Waters). Mobile phase A consisted of 0.1% formic acid in water (Milli-Q) and mobile phase B consisted of 0.1% formic acid in ACN. The following linear gradients were used at a flow rate of 0.5 mL/min: time scale (min-min) mobile phase A (%)/mobile phase B (%): 0-2.5 95/5 / 2.5-3.5 10/ 90 / 3.5-4.0 95/5. The column temperature was kept at 408C and the autosampler temperature at 48C The LC eluate was directed into a tandem quadruple, atmospheric pressure ionization mass spectrometer (TQ-S micro; Acquity, Waters) equipped with an electrospray ionization source.
Mass Spectrometric Conditions
The mass spectrometer was operated in the positive-ion mode and configured in multiple reaction monitoring mode for detection of enzalutamide (m/z 465 / 209), N-desmethylenzalutamide (m/z 451 / 195), and D 6 -enzalutamide (m/z 471 / 215) ( Table 1 ). For both enzalutamide and Ndesmethylenzalutamide, the following optimized settings on the mass spectrometer were used: capillary voltage was 4.2 kV, cone voltage was 65 V, desolvation temperature was 5008C, and desolvation gas flow was 1000 L/h. Collision energy was 25 V, dwell time was 0.05 seconds, and typical retention time for enzalutamide and D 6 -enzalutamide was 2.5 minutes and for N-desmethylenzalutamide 2.4 minutes.
The data were acquired and processed using Masslynx Software (version 4.1; Waters, Etten-Leur, the Netherlands).
Quantification
Enzalutamide and N-desmethylenzalutamide were quantified in plasma by describing the relationship between the peak area ratio to the internal standard versus the nominal concentration. A quadratic curve with 1/x as weighing factor was used to quantify enzalutamide and N-desmethylenzalutamide that resulted in a better fit than a more simple linear relationship. The range of the calibration curve was chosen to cover the clinically relevant concentrations that are expected in patients treated with the recommended dose. The lower limit of quantification (LLOQ) and higher limit of quantification (HLOQ) were selected at the outer range of the concentration levels measured in patients treated with enzalutamide 160 mg OD.
Validation Procedures
The validation of the assay was performed according to the European Medicines Agency (EMA) guidelines for validation of bioanalytical assays including calibration curve, carry-over, precision, accuracy, selectivity, dilution integrity, matrix factor (MF), recovery, and stability. 7 
RESULTS
Assay Development
Because of the high plasma levels expected in patient samples, a human albumin solution (Albuman) was used for an initial dilution step to prevent saturation of the mass spectrometry (MS) signal and to reduce the amount of compound (enzalutamide and N-desmethylenzalutamide) needed for preparing calibration solutions. Furthermore, because of this dilution step, a virtually equal matrix was achieved for all standards, QCs, and samples.
Assay Validation Calibration Curve
The calibration curve was prepared and analyzed by measuring 7 nonzero calibration standards in 3 independent analytical runs. A quadratic curve with 1/x as the weighing factor proved to be the most optimal description of the relationship between the concentration and area ratio (Fig. 1) . At all concentration levels (500-50,000 ng/mL), the deviations of the back-calculated concentrations were within 615% of the nominal concentrations. This is in accordance to the EMA guidelines. 7 
Benoist et al
Ther Drug Monit Volume 40, Number 2, April 2018
Carry-Over
Carry-over was tested by injecting a blank sample after the highest calibration standard, and this was repeated 5 times. For both enzalutamide and N-desmethylenzalutamide, no eluting peaks with areas of .20% of the LLOQ were observed. For the internal standard, no eluting peaks with areas of .5% of the normal response of D 6 -enzalutamide were observed. Carry-over was therefore considered to be acceptable.
Precision, Accuracy
The within-run and between-run precision and accuracy were determined. To test the within-run precision, 5 replicates of the QC samples at all concentration levels [QC LLOQ, QC low (QCL), QC medium (QCM), QC high (QCH), and QC HLOQ] were analyzed in one analytical run. To test the between-run precision, the same QC samples were analyzed in 3 analytical runs on 3 different days. For QCL, QCM, QCH, and QC HLOQ, precision, expressed as coefficients of variation (CVs) values, was below 5% for enzalutamide and 8% for Ndesmethylenzalutamide. Accuracy, expressed as deviations from the nominal concentrations, was within 108% for both enzalutamide and N-desmethylenzalutamide, respectively. For QC LLOQ, the precision was below 5% for enzalutamide and within 610% for N-desmethylenzalutamide, and accuracy was within 109 and 116% for enzalutamide and N-desmethylenzalutamide, respectively. Therefore, the precision and accuracy were within the acceptance criteria of the EMA guidelines.
Selectivity
The selectivity of the assay was tested in 6 different batches of blank control plasma. The blank controls showed no peaks coeluting with enzalutamide, N-desmethylenzalutamide, and D 6-enzalutamide. The maximum peak area was ,2% of the signal of LLOQ of enzalutamide and ,3% of LLOQ of Ndesmethylenzalutamide. Based on these results, we concluded that the selectivity was sufficient and that the assay was suitable for the detection of the analytes in plasma.
Dilution Integrity
To demonstrate dilution integrity, 3 replicate plasma samples of enzalutamide and N-desmethylenzalutamide at 1.5*HLOQ level (75,000 ng/mL) were diluted 2-and 4-fold with blank plasma. The mean accuracy after 2-and 4-fold dilution, respectively, was 101 and 98% for enzalutamide and 107 and 103% for N-desmethylenzalutamide. The mean precision after 2-and 4-fold dilution, respectively, was 2.8 and 2.5% for enzalutamide and 5.9 and 2.2% for N-desmethylenzalutamide.
Matrix Factor
The MF was determined in 6 different plasma samples at QCL and QCH concentration levels. The MF in albuman/plasma (90/10) for enzalutamide ranged from 0.99 to 1.03 and for Ndesmethylenzalutamide from 1.3 to 1.4. The MF of 1.4 indicated enhancement of the response due to matrix effects. The maximum CV of the IS-normalized MF calculated from the 6 different plasma samples for the low and the high concentration was, respectively, 1.0 and 0.9% for enzalutamide and 1.0 and 2.7% for N-desmethylenzalutamide, fulfilling the acceptance criteria of ,15%. 7 The assay performance data are summarized in Table 2 .
Recovery
The recovery, covering sample preparation, and stability were determined at 3 concentration levels (1000, 15,000, and 40,000 ng/mL) in duplicate, for enzalutamide and Ndesmethylenzalutamide and for the internal standard D 6 -enzalutamide. In plasma, the mean recovery of enzalutamide was 100% with a CV of 2%; for N-desmethylenzalutamide, it was 141% with a CV of 2%; and for the internal standard, the mean recovery was 102% with a CV of 2%. The high recovery of N-desmethylenzalutamide is likely to be caused by enhancement of the response because of matrix effect. Differences in recovery are corrected for by the internal standard used.
Stability
Enzalutamide and N-desmethylenzalutamide and the internal standard (D 6 -enzalutamide) were stable for at least 11 months in stock solution at 2408C.
The autosampler stability (at 2-88C) for enzalutamide and N-desmethylenzalutamide was demonstrated to deviate not more than 4 and 11% after 7 days. Freeze-thaw stability experiments did not demonstrate degradation of enzalutamide and N-desmethylenzalutamide over 3 freeze-thaw cycles. The long-term stability, as tested in QC samples, was at least 11 months at 2408C. The short-term patient sample stability was demonstrated for enzalutamide and N-desmethylenzalutamide for at least 23 days in plasma at ambient temperature and at 48C. The whole blood patient sample stability was shown for 24 hours at ambient temperature. The long-term patient sample stability was demonstrated for enzalutamide and N-desmethylenzalutamide for 14 months at 2408C (Table 3) .
External Validation
For the external validation, duplicate sets of blinded QCs at the 3 concentration levels were exchanged with the University of Pittsburgh Cancer Institute where a validated enzalutamide assay is in use. 8 The nominal enzalutamide and N-desmethylenzalutamide concentrations of 15,000 and 50,000 ng/mL (QCM and QCH) were within the calibration curve of the assay used in Pittsburg, and the results were 65.5% of the actual concentration. The exchanged QCL was below the limit of detection of the assay used in Pittsburg and could therefore not be interpreted.
CLINICAL APPLICABILITY
To test the applicability of this assay, enzalutamide and N-desmethylenzalutamide concentrations were quantified in samples collected from a patient participating in a clinical trial who was treated with 160-mg enzalutamide OD and had reached steady-state pharmacokinetics. Figures 2 and 3 show chromatograms and a pharmacokinetic curve of a patient in this trial. Patient demographic data and specimens were used in accordance with the principles of the Declaration of Helsinki. The protocol of this study was approved by the ethics committee of Medical ethical committee of ArnhemNijmegen, the Netherlands.
The applicability of this assay was investigated in samples of a patient treated with enzalutamide (160 mg OD) because of clinical problems that were encountered in his treatment.
Patient A
A 57-year-old male patient with mCRPC started enzalutamide therapy in January 2015. From March 2015, he suffered long-term fatigue, malaise, and decreased appetite as well as joint pain. In July 2015, the treating physician decided, in consultation with the clinical pharmacologist, to decrease the dose to 120 mg and to measure plasma concentrations before and after dose reduction. Because no target concentration for efficacy has been identified, the population average concentration of enzalutamide and Ndesmethylenzalutamide was used. 9 The average concentrations were divided in quartiles (median Q1-Q4 [19.35-29.65 mg/L]). No difference in overall survival was demonstrated between the quartiles. Plasma concentrations before dose reduction were within the third concentration quartile (Fig. 4) . 9 Tiredness and especially complaints regarding malaise improved 1 month after dose reduction. The plasma concentrations were within the second quartile after dose reduction and were therefore adequate. The patient continued treatment with 120 mg enzalutamide until October 2016. In Figure 4 , plasma concentrations and prostatespecific antigen levels are shown. Prostate-specific antigen levels remained stable during therapy and plasma levels remained within the median quartiles reported by Gibbons et al. 9 
DISCUSSION
We have developed a new method to quantitate enzalutamide and its active metabolite N-desmethylenzalutamide in human plasma. Previously, 3 LC-MS/MS methods were published. 6, 8, 10 During development of our method, we expected that the high concentration of enzalutamide could cause saturation of the MS signal, and therefore we introduced a dilution step with albuman/plasma (90:10) for calibrators, QCs, and patient samples. All previously published methods used a different approach to overcome this challenge; the method of Bennett et al did not explicitly describe the issue of MS signal saturation, and the low recovery described in this method resulting in a lower MS signal might explain that this issue was not encountered. Moreover, the internal standard that was used ( 13 CD 3 -enzalutamide) was labeled in the N-methyl function group. This group is susceptible to metabolism and chemical hydrolysis during sample preparation, potentially giving rise to the formation of the major metabolite N-desmethylenzalutamide. 6 Therefore, this internal standard is not the preferred isotopomer. The method of van Nuland et al described the issue concerning saturation of the MS signal and therefore diluted the patient samples before analysis. This is comparable with our approach. The main difference is the dilution medium albuman/plasma (90:10) we used in our method, which is a more reproducible matrix over time compared with purchased human blank plasma. 10 In addition, in our method, all samples underwent similar sample pretreatment (standards, QCs, and patient samples), whereas van Nuland et al only diluted the patient samples, which might introduce dilution integrity issues. The bioanalytical method of Kim et al 8 used an isotopolog multiple reaction monitoring method whereby the signal was diluted by a factor 12 to prevent saturation of the MS signal and to increase the linear dynamic range of the method. In conclusion, all previous publications aimed for a very sensitive method with a wide linear dynamic range while avoiding saturation of the MS signal. In our study, we showed that enzalutamide and N-desmethylenzalutamide are stable in whole blood for 24 hours, and that, patient plasma samples are stable at ambient temperature for 23 days. This information is of value for the practical aspects of collection and shipment of patient samples. Two of the previously published methods did not describe whole blood stability of patient samples, and Kim et al did describe whole blood stability but tested this for a much shorter period (4 hours). 6, 8, 10 Enzalutamide is widely prescribed for patients with mCRPC and is generally well tolerated. As dose-dependent fatigue is the most common reported adverse event, 11, 12 we routinely measure enzalutamide in routine patient care as described above for our patient A.
CONCLUSIONS
A selective, sensitive, and practical bioanalytical method to quantitate enzalutamide and N-desmethylenzalutamide was successfully developed and validated according to the EMA guidelines. The method will be used to support pharmacokinetic studies and for routine patient care in cases where unexpected toxicity, inefficacy, and drug interactions are suspected.
